Drug Therapy for Hereditary Cancers
Author Information
Author(s): Evgeny N Imyanitov, Vladimir M Moiseyenko
Primary Institution: N.N. Petrov Institute of Oncology, St.-Petersburg, Russia
Hypothesis
Tumors arising in patients with hereditary cancer syndromes may have distinct drug sensitivity compared to sporadic tumors.
Conclusion
Hereditary cancers, particularly those associated with BRCA1 and BRCA2 mutations, show unique drug sensitivities that can inform tailored treatment strategies.
Supporting Evidence
- BRCA1 and BRCA2 mutations lead to distinct drug sensitivities in breast and ovarian cancers.
- Patients with BRCA1-related breast cancer may benefit less from taxane-based treatments.
- High sensitivity to platinum compounds has been observed in BRCA1 and BRCA2 mutation carriers.
Takeaway
Some cancers that run in families respond better to certain medicines than other cancers that don't run in families. This means doctors can choose better treatments for these patients.
Methodology
The article reviews existing literature on drug responses in hereditary cancers, particularly focusing on BRCA1 and BRCA2 mutations.
Limitations
The review is based on existing literature, which may not cover all hereditary cancers or treatments comprehensively.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website